Article Details
Retrieved on: 2024-04-23 09:03:57
Tags for this article:
Click the tags to see associated articles and topics
Summary
Verona Pharma's ensifentrine, a treatment for COPD, awaits FDA approval with a PDUFA date set for June 26. Canaccord Genuity analyst projects a significant stock price increase upon approval. The article also discusses Verona's commercialization plans and future clinical trials. Key tags such as 'biopharma', 'chronic obstructive pulmonary disease', and 'pharmaceutical industry in China' are related to the article's focus on the pharmaceutical industry, drug approval processes, and market analysis.
Article found on: www.streetwisereports.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here